Reuters
26 Aug 2026, 06:56 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
1 claim · each scored for market impact
Biohaven entered a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform, including Opakalim, for up to $795 million. — Significant non-dilutive funding and validation of the drug platform provide a substantial boost to Biohaven's balance sheet and valuation.
+0.60Which stocks this story touches
Continue reading
6 related stories
Search tags
[mutual] Biohaven entered into a licensing agreement with SK Biopharmaceuticals for its epilepsy drug platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Accesswire
2h ago
